Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System
- 776 Downloads
Immunotherapy is a promising therapeutic strategy in the treatment of lymphoma. The programmed death-1 (PD-1)/PD-ligand immune checkpoint pathway has been manipulated by tumor cells and serves as a mechanism of tumor evasion from the anti-tumor immune response. The recent development of anti-PD-1 antibodies has offered a therapeutic strategy for restoring the function of exhausted antigen-specific T cells and enhancing the endogenous anti-tumor immunity. We review the clinical studies demonstrating efficacy and safety of PD-1 antibodies in relapsed/refractory Hodgkin, follicular, and diffuse large B cell lymphoma. Principles learned in the development of immune checkpoint blockade provide the foundation for immunotherapy under clinical investigation.
KeywordsLymphoma Checkpoint Programmed death-1 Monoclonal antibody
This work was supported by grants from the National Institutes of Health R01 CA155143 (SSN), the Leukemia and Lymphoma Society P-QFC-3068-14 (SSN), and the Cancer Prevention and Research Institute of Texas RP150318 (SSN). We thank Mark Nastoupil for assistance with the illustration.
Compliance with Ethics Guidelines
Conflict of Interest
Loretta J. Nastoupil has received compensation from Celgene and Genentech for service as a consultant.
Sattva S. Neelapu has received research support from Bristol-Myers Squibb, CureTech, Celegene, and Merck, and has received compensation from Celgene for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013;31:860–7.CrossRefPubMedGoogle Scholar
- 12.Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200.CrossRefPubMedGoogle Scholar
- 17.Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77.CrossRefPubMedCentralPubMedGoogle Scholar
- 20.•Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9. This phase 1 study reported an 87 % overall response rate with nivolumab (anti-PD-1) in heavily pre-treated relapsed or refractory HL patients leading to FDA approval for Breakthrough Therapy Designation for patients who have failed autologous stem cell transplant and brentuximab therapy.CrossRefPubMedGoogle Scholar
- 21.Moskowitz CH, Ribrag, V, Michot, J, et al. (2014) PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood. ASH 2014 Abstracts, Session 624; Abstract:290 2014.Google Scholar
- 27.•Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. This is a phase 2 study reported on the efficacy and safety of pidilizumab (anti-PD-1) in combination with rituximab in relapsed FL. Two-thirds of patients responded, with the majority of responses consisting of a CR (52 %). Correlate work supports the rationale of targeting the endogenous anti-tumor immunity in FL and suggests synergy with agents like rituximab which may enhance NK-mediated immunity.CrossRefPubMedCentralPubMedGoogle Scholar
- 34.Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206.CrossRefPubMedGoogle Scholar
- 35.Lesokhin AM, Ansell SM, Armand P, et al. (2014) Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood. ASH 2014 Abstracts, Session 624; Abstract:291 2014.Google Scholar
- 44.Schadendorf D, Hodi FS, Robert C et al. (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015.Google Scholar
- 55.Kotaskova J, Tichy B, Trbusek M, et al. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn. 2010;12:328–34.CrossRefPubMedCentralPubMedGoogle Scholar